What Dermapharm AG does

Dermapharm AG is a Swiss pharmaceutical company founded in 1995 and headquartered in Hünenberg ZG. It operates as the Swiss subsidiary of the Dermapharm Unternehmensgruppe, a family-managed German corporate group. The company's core business is the development, manufacturing, and distribution of high-quality dermatological and anti-inflammatory pharmaceutical products, with its own production facility located in Brehna, Germany. It positions itself as a reliable partner for patients, doctors, pharmacists, and other stakeholders in the Swiss national healthcare system, operating through a sales-led, relationship-driven distribution model that routes products via the Swiss pharmacy network under Swiss pharmaceutical regulations.

The company has expanded its Swiss portfolio through three strategic acquisitions: Allergopharma AG in 2021 (allergy medications), Arkopharma AG (Arko Diffusion SA) in 2023 (phytotherapy and dietary supplements), and Candoro ethics AG in 2023 (narcotics and controlled substances). These integrations have systematically broadened Dermapharm AG's therapeutic footprint beyond dermatology into adjacent pharmaceutical categories, while drawing on the parent group's broader portfolio of brands including mibe arzneimittel, Strathmann, Trommsdorff, huebner naturarzneimittel, axi corp pharma, and acis.

Dermapharm AG is a private company with no publicly disclosed revenue, headcount, or pricing data. Revenue mechanics are based on pharmaceutical product sales through the Swiss healthcare and pharmacy channel, with three integrated acquired brands contributing to top-line diversification. The company's addressable market is the Swiss national healthcare system, and its geographic focus remains domestic despite the parent group's broader European presence.

Name

Dermapharm AG

Legal name

Dermapharm AG

Website

https://dermapharm.ch

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

101–250 employees

Short description

Dermapharm AG is a Swiss pharmaceutical subsidiary founded in 1995 that develops, manufactures, and distributes dermatological, anti-inflammatory, allergy, phytotherapy, and narcotics products for the Swiss healthcare market from its Hünenberg headquarters.

Ownership category

akta.pro rank

Product category

Dermatological Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Dermatology Specialty Pharmaceuticals (HLAIACAL)

akta.pro secondary industries

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF), Topical & Dermatology Generics (HLAIABAE)

Keywords

• Dermatological pharmaceuticals
• Anti-inflammatory medicines
• Pharmaceutical manufacturing
• Allergy medications
• Phytotherapy supplements

Headquarters

HQ city

Hünenberg ZG

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D

Revenue model

1. Pharmaceutical Development and Distribution: Development, manufacturing, and distribution of high-quality dermatological and anti-inflammatory pharmaceutical products. The company operates through its Swiss subsidiary to serve the Swiss market.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Dermapharm AG develops, manufactures, and distributes high-quality dermatological and anti-inflammatory pharmaceutical products for the Swiss healthcare market. Through its own pharmaceutical production facility in Brehna, Germany, and acquired brands (Allergopharma, Arkopharma, Candoro ethics), the company offers a portfolio spanning dermatology, allergy, phytotherapy/dietary supplements, and narcotics to patients, doctors, pharmacists, and national healthcare stakeholders in Switzerland.

Product overview

Dermapharm AG is a family-owned pharmaceutical company founded in 1995, based in Hünenberg ZG, Switzerland, with its own pharmaceutical production facility in Brehna, Germany. The company operates as a single brand portfolio focused on high-quality dermatological and anti-inflammatory medications for the Swiss healthcare market. The Dermapharm group has expanded through strategic acquisitions: Allergopharma AG (2021) for allergy treatments, Arkopharma AG (2023) for phytotherapy and dietary supplements, and Candoro ethics AG (2023) for narcotics. The group encompasses multiple subsidiaries including mibe arzneimittel, Strathmann, Trommsdorff, Mibetec, axi corp pharma, huebner naturarzneimittel, and acis, all serving various segments of the pharmaceutical industry across Europe.

Differentiator

Problem solved

Functional benefit

Brands

• mibe arzneimittel: Pharmaceutical company within the Dermapharm group
• strathmann
• Trommsdorff
• allergopharma
• candoro ethics
• mibetec
• axicorp pharma
• huebner naturarzneimittel
• acis

Products and services

• Dermatological and Anti-inflammatory Pharmaceuticals High-quality dermatological and anti-inflammatory pharmaceutical products manufactured at the group's own production facility in Brehna, Germany, and distributed to patients, doctors, pharmacists, and stakeholders in the Swiss national healthcare system.
• Allergopharma AG - Allergy Pharmaceuticals Allergy-focused pharmaceutical products distributed under the Allergopharma brand, serving patients, doctors, and pharmacists in Switzerland with allergy therapeutics.
• Arkopharma AG (Arko Diffusion SA) - Phytotherapy and Dietary Supplements Phytotherapy and dietary supplement products distributed under the Arkopharma brand in Switzerland, providing herbal medicines and nutritional supplements to patients and pharmacy partners.
• Candoro ethics AG - Narcotics/Anaesthetics Pharmaceuticals Narcotics and anaesthetics pharmaceutical products distributed under the Candoro ethics brand, serving controlled-substance prescribing and dispensing needs in the Swiss healthcare system.

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Three partnerships are on record, tiered core.

• Arkopharma AG (Arko Diffusion SA)coreStrategic or Co-development Partner · 1 January 2023Acquired in 2023, Arkopharma AG expanded Dermapharm's competencies in phytotherapy and nutritional supplements in the Swiss market.
• Candoro ethics AGcoreStrategic or Co-development Partner · 1 January 2023Acquired in 2023, Candoro ethics AG expanded Dermapharm's competencies in controlled substances/narcotics in the Swiss market.
• Allergopharma AGcoreStrategic or Co-development Partner · 1 January 2021Acquired in 2021, Allergopharma AG expanded Dermapharm's competencies in the allergy sector within the Swiss market.

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Regional players

• Hänseler AG: Swiss pharmaceutical wholesale and distribution company serving pharmacies, physicians, and hospitals. Comparable to Dermapharm AG as a Switzerland-focused pharmaceutical distribution counterpart with overlapping Swiss pharmacy channel presence.
• Spirig HealthCare AG: Swiss dermatology pharmaceutical and dermo-cosmetic company with a strong local footprint. Highly comparable to Dermapharm AG in Swiss-market-only focus, dermatology and skin-care product categories, and pharmacy-channel distribution model.

Broad incumbents

• Haleon: Global consumer healthcare company with dermatology and oral health franchises. Comparable to Dermapharm AG in pharmacy-channel distribution and OTC dermatology, though at significantly larger scale and broader category breadth.
• Bayer Consumer Health: Major pharmaceutical and consumer health player with dermatology and skin-care brands (e.g., Bepanthen). Comparable to Dermapharm AG as an incumbent selling dermatology products through Swiss pharmacies, though within a much larger diversified portfolio.
• Dermapharm Holding SE: German parent company of Dermapharm AG and a publicly listed pharmaceutical group with a portfolio spanning dermatology, allergy, vitamins, and generics. Closely related through shared ownership and shared production facility in Brehna; serves as the umbrella entity whose strategy shapes Dermapharm AG's direction.

Direct peers

• Galderma: Global dermatology-focused pharmaceutical company with a broad prescription and aesthetics portfolio. Directly comparable to Dermapharm AG's core dermatology franchise and Swiss market presence through prescription dermatology products sold via pharmacies.
• Almirall: European dermatology-focused pharmaceutical company with a portfolio of prescription and dermo-cosmetic products. Comparable to Dermapharm AG in mid-sized dermatology player positioning, pharmacy-channel distribution, and emphasis on inflammatory skin conditions.
• Pierre Fabre: French pharmaceutical and dermo-cosmetic group with a leading dermatology franchise. Comparable to Dermapharm AG in the combination of prescription dermatology, dermo-cosmetics, and integrated manufacturing for skin-care products sold through pharmacy channels.
• LEO Pharma: Specialist dermatology pharmaceutical company with strong prescription portfolios in psoriasis, eczema, and skin infections. Comparable to Dermapharm AG in therapeutic focus, channel model (specialists and pharmacies), and regulatory positioning across European markets including Switzerland.
• Stada Arzneimittel AG: European generics and specialty pharmaceutical company with a strong dermatology and consumer health portfolio. Comparable to Dermapharm AG in the combination of branded generics, specialty pharma, and broad European pharmacy distribution including Switzerland.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/dermapharm-ag-ch

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dermapharm AG